As of January 22, 2025, Perspective Therapeutics (CATX) has a market cap of $0.24 billion USD. According to our data, Perspective Therapeutics is ranked No.6908 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.24 B |
12.85%
|
Dec 31, 2024 | $0.22 B |
-20.25%
|
Dec 29, 2023 | $0.27 B |
60.00%
|
Dec 30, 2022 | $0.17 B |
-35.90%
|
Dec 31, 2021 | $0.26 B |
-13.33%
|
Dec 31, 2020 | $0.30 B |
-27.42%
|
Dec 31, 2019 | $0.42 B |
106.67%
|
Dec 31, 2018 | $0.20 B |
-25.00%
|
Dec 29, 2017 | $0.27 B |
-31.03%
|
Dec 30, 2016 | $0.39 B |
-38.30%
|
Dec 31, 2015 | $0.64 B |
-35.62%
|
Dec 31, 2014 | $0.99 B |
192.00%
|
Dec 31, 2013 | $0.34 B |
-35.90%
|
Dec 31, 2012 | $0.53 B |
18.18%
|
Dec 30, 2011 | $0.45 B |
-41.59%
|
Dec 31, 2010 | $0.76 B |
26.97%
|
Dec 31, 2009 | $0.60 B |
345.00%
|
Dec 31, 2008 | $0.14 B |
-90.05%
|
Dec 31, 2007 | $1.36 B |
-58.98%
|
Dec 29, 2006 | $3.31 B |
-32.41%
|
Dec 30, 2005 | $4.90 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Novartis
NVS
|
$196.27 B |
-0.007 M
|
Switzerland
|
Pfizer
PFE
|
$147.40 B |
-0.003 M
|
USA
|
Merck
MRK
|
$242.04 B |
-0.000 M
|
USA
|
Johnson & Johnson
JNJ
|
$349.75 B |
0.001 M
|
USA
|
Amgen
AMGN
|
$146.98 B |
0.004 M
|
USA
|
Gilead Sciences
GILD
|
$115.95 B |
0.002 M
|
USA
|
Bristol-Myers Squibb
BMY
|
$115.79 B |
-0.003 M
|
USA
|
AbbVie
ABBV
|
$299.00 B |
-0.007 M
|
USA
|
Eli Lilly
LLY
|
$678.07 B |
0.022 M
|
USA
|
Biogen
BIIB
|
$20.80 B |
0.000 M
|
USA
|
Regeneron Pharmaceuticals
REGN
|
$74.73 B |
1.236 B
|
USA
|
Sanofi
SNY
|
$129.14 B |
0.001 M
|
France
|
AstraZeneca
AZN
|
$211.49 B |
0.007 M
|
UK
|
GlaxoSmithKline
GSK
|
$68.21 B |
-0.002 M
|
UK
|
Market Cap | = | CATX Stock Price | * | CATX Shares Outstanding |
= | $3.60 | * | 67.59 M | |
= | $0.24 B |